Healthcare
REGENXBIO Inc.(RGNX)
Live Price
Offline$7.80
-1.27% today
1Y Change
-15.27%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $470.00M
- Revenue Growth
- +104.5%
- EPS Growth
- +18.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
REGENXBIO Inc. (RGNX) is a Healthcare stock with a market cap of $470.00M and listed on NASDAQ. The stock last traded around $7.80 and down 15.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +104.5%, EPS growth of +18.1%, a dividend yield of 0.0%. What stands out right now is revenue +104.5%, EPS +18.1%, free cash flow +28.0% with operating margin -94.6% and ROIC -42.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RGNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+104.5% vs +7.6% peer median
Operating Margin
Below sector median
-94.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +104.5% and EPS at +18.1%, with operating margin around -94.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +1.6% | -43.9% | -37.1% |
2026 Mar 5, 2026 | -28.7% | -0.8% | +4.1% | -2.2% |
2025 Nov 6, 2025 | +13.0% | +0.4% | +4.2% | +17.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGNX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGNX Max Drawdown
-64.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGNX and SPY.
Company Overview
REGENXBIO Inc.
NASDAQ Global Select
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
- Leadership
- Curran Simpson
- IPO Date
- Sep 17, 2015
- Employees
- 353
- Street Address
- 9804 Medical Center Drive
- Mailing
- Rockville, MD, 20850
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 552 8181
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.8
- Price/Book
- 4.6
Growth
- Revenue
- +104.5%
- EPS
- +18.1%
- Free Cash Flow
- +28.0%
Profitability
- Gross Margin
- 52.9%
- Operating Margin
- -94.6%
- Net Margin
- -113.8%
- ROE
- -103.1%
- ROIC
- -42.1%
Balance Sheet
- Debt/Equity
- 2.54
- Current Ratio
- 2.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.